Intensity Therapeutics, Inc.INTSNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank63
3Y CAGR-50.9%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-50.9%/yr
Quarterly compound
Percentile
P63
Within normal range
vs 3Y Ago
0.1x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q3 2025 | 1.37% |
| Q2 2025 | -3.40% |
| Q1 2025 | -2.51% |
| Q4 2024 | -12.90% |
| Q3 2024 | -5.78% |
| Q2 2024 | -21.64% |
| Q1 2024 | 23.89% |
| Q4 2023 | 36.21% |
| Q3 2023 | 251.68% |
| Q2 2023 | -14.74% |
| Q1 2023 | -34.96% |
| Q4 2022 | -3.80% |
| Q3 2022 | 11.64% |
| Q2 2022 | -20.49% |
| Q1 2022 | -29.68% |
| Q4 2021 | 52.11% |
| Q3 2021 | 144.95% |
| Q2 2021 | -8.09% |
| Q1 2021 | 13.35% |
| Q4 2020 | 0.00% |